Hangzhou Hanx Biopharmaceuticals, Ltd.
Clinical trials sponsored by Hangzhou Hanx Biopharmaceuticals, Ltd., explained in plain language.
-
New Dual-Action antibody shows promise for tough lymphoma cases
Disease control CompletedThis study tested a new drug called HX009 in 48 Chinese patients whose lymphoma had returned or stopped responding to standard treatments. HX009 is a special antibody that targets two proteins (CD47 and PD-1) on cancer cells to help the immune system attack them. The main goal wa…
Phase: PHASE1, PHASE2 • Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd. • Aim: Disease control
Last updated May 26, 2026 09:30 UTC
-
New antibody combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called HX009 in 20 adults with advanced solid tumors that had not responded to standard treatments. HX009 is a bifunctional antibody designed to help the immune system attack cancer cells. The main goal was to see if the drug could shrink tumors, and …
Phase: PHASE2 • Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd. • Aim: Disease control
Last updated May 26, 2026 08:33 UTC